Astellas Reports Full Year FY2016 Financial Results (462 KB)
(WorldNews Japan)

Press Release Astellas Reports Full Year FY2016 Financial Results - Sales decreased (-4.4%) on a reported basis and increased approximately 2% excluding the factors associated with the transfer of the global dermatology business implemented in April 2016 and the impact of the foreign exchange; Increased core operating profit (+2.7%) and core profit (+7.3%) Sales of XTANDI® (enzalutamide) and overall overactive bladder ("OAB") treatments steadily increased on a constant currency basis Sales in the Americas, EMEA1, Asia and Oceania decreased while increased on a constant currency basis. Sales in Japan decreased due to impacting factors such as a National Health Insurance...